Movatterモバイル変換


[0]ホーム

URL:


CN103387572B - Everolimus defects inspecting reference marker and preparation method thereof - Google Patents

Everolimus defects inspecting reference marker and preparation method thereof
Download PDF

Info

Publication number
CN103387572B
CN103387572BCN201310300574.6ACN201310300574ACN103387572BCN 103387572 BCN103387572 BCN 103387572BCN 201310300574 ACN201310300574 ACN 201310300574ACN 103387572 BCN103387572 BCN 103387572B
Authority
CN
China
Prior art keywords
everolimus
reference marker
impurities
organic solvent
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310300574.6A
Other languages
Chinese (zh)
Other versions
CN103387572A (en
Inventor
朱辉
范雪涛
杨益
韩晓彤
黄定均
陈冬芝
黎正伟
范洁瑜
陈嘉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU YATU BIOTECHNOLOGY Co Ltd
Original Assignee
CHENGDU YATU BIOTECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHENGDU YATU BIOTECHNOLOGY Co LtdfiledCriticalCHENGDU YATU BIOTECHNOLOGY Co Ltd
Priority to CN201310300574.6ApriorityCriticalpatent/CN103387572B/en
Publication of CN103387572ApublicationCriticalpatent/CN103387572A/en
Application grantedgrantedCritical
Publication of CN103387572BpublicationCriticalpatent/CN103387572B/en
Activelegal-statusCriticalCurrent
Anticipated expirationlegal-statusCritical

Links

Landscapes

Abstract

The invention discloses a kind of everolimus defects inspecting reference marker and preparation method thereof, belong to a kind of everolimus defects inspecting technology, this reference marker is a kind of degraded product of everolimus, alkaline solution is adopted to dissolve everolimus solid, utilize alkali in organic acid He excessive after reacting by heating, the mixture after neutralization is condensed into mixture solid; Adopt water-containing organic solvent dissolving mixt solid, adopt water-containing organic solvent as strippant, desorb chromatography column, Fractional Collections contains the strippant of target product, concentrates and obtains everolimus defects inspecting reference marker; Everolimus defects inspecting reference marker of the present invention and preparation method thereof provide a kind of structure reference marker identical or close with the chemical derivative in everolimus impurity, synthesising by-product and degraded product and preparation method thereof, effectively improve science and the accuracy of everolimus defects inspecting.

Description

Reference marker for everolimus impurity detection and preparation method thereof
Technical Field
The invention relates to an everolimus impurity detection technology, in particular to a reference marker for everolimus impurity detection and a preparation method thereof.
Background
Everolimus is a rapamycin derivative with certain water solubility developed by noval corporation, switzerland, is mainly used clinically to prevent rejection after kidney transplantation and heart transplantation operations, and can be orally administered. The action mechanism mainly comprises an immunosuppressive action, an antitumor action, an antiviral action and a blood vessel protection action, and is often used in combination with other immunosuppressive agents such as cyclosporine and the like to reduce toxicity. In addition, everolimus is also used for the treatment of advanced renal cancer.
It is well known that for the production of active pharmaceutical ingredients for human administration, the requirements for the content of impurities are very high. Generally, a weight ratio of each impurity content of less than 0.15% is required, and a weight ratio of less than 0.1% is required for an unidentified impurity content with undetermined toxicity. However, impurities in the active pharmaceutical ingredient are widely available, may result from degradation of the product itself (which is related to the stability of the product during storage), and may also result from manufacturing processes (including chemical synthesis). The impurities derived from the preparation method include unreacted starting materials, impurities contained in the starting materials and chemical derivatives thereof, synthesis by-products, degradation products, and the like.
In the technical field of medical quality analysis, chemical derivatives, synthesis byproducts and degradation products in active pharmaceutical ingredient impurities can be identified by adopting a spectrum or other physical methods, and the impurities have a correlation with peak positions in a chromatogram, so that the impurities can be identified according to the relative positions of the impurities in the chromatogram. Before analyzing impurities in a compound, a substance with higher purity and the same or similar structure as the impurities is used as a reference marker, a pure compound to be detected is used as a reference standard, the reference marker and the reference standard are detected together, the relative position of the reference marker in a chromatogram is taken as the relative position of the impurities in the chromatogram, and the impurity detection of the compound to be detected is guided. Obviously, the selection and preparation of the reference marker has a direct impact on the scientificity and accuracy of the detection of the impurity content in the active pharmaceutical ingredient. For the detection of the content of the everolimus impurities, a substance reference marker which has the same or similar structure as the chemical derivatives, the synthesis byproducts and the degradation products in the everolimus impurities and has higher purity needs to be selected and prepared, so that the scientificity and the accuracy of the detection of the everolimus impurities are improved.
Disclosure of Invention
In order to improve the scientificity and accuracy of everolimus impurity detection, the invention provides a reference marker for everolimus impurity detection and a preparation method thereof.
The reference marker for detecting the everolimus impurities is a degradation product of everolimus, and the structure of the reference marker is as follows:
according to the preparation method of the reference marker for detecting the everolimus impurities, provided by the invention, the solid everolimus is dissolved by using an alkali solution, excessive alkali is neutralized by using an organic acid after heating reaction, and a neutralized mixture is concentrated into a mixture solid; dissolving the mixture solid by using an aqueous organic solvent, desorbing the chromatographic column by using the aqueous organic solvent as a desorbent, collecting the desorbent containing the target product in sections, and concentrating to obtain a reference marker for detecting the everolimus impurities; wherein,
the alkali solution is one of sodium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium hydroxide, dipotassium hydrogen phosphate and potassium dihydrogen phosphate, and the concentration of the solution is 0.2 to 0.7 mol/L;
the heating reaction temperature is 20 to 90 ℃;
the organic acid is one of formic acid, acetic acid, oxalic acid, benzoic acid and succinic acid;
the concentration temperature is 30-60 ℃, and a rotary evaporator is adopted for concentration;
the water-containing organic solvent is one of water solutions of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content of the water-containing organic solvent is 20 to 80 weight percent;
the silica gel column is one of C1, C4, C8 and C18 reverse phase silica gel;
the desorbent is one of water-containing organic solvents of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content is 30-70 wt%.
Further, the preparation method of the reference marker for detecting everolimus impurities comprises the following steps:
s1, dissolving everolimus solid by adopting an alkali solution, wherein the alkali solution is one of sodium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium hydroxide, dipotassium hydrogen phosphate and potassium dihydrogen phosphate, and the concentration of the solution is 0.2-0.7 mol/L;
s2, heating for reaction, wherein the heating reaction temperature is 20-90 ℃;
s3, neutralizing the everolimus solution by using organic acid, wherein the organic acid is one of formic acid, acetic acid, oxalic acid, benzoic acid and succinic acid;
s4, concentrating the mixture, and concentrating the mixture at 30-60 ℃ by adopting a rotary evaporator to prepare a mixture solid;
s5, dissolving the solid mixture prepared in the step S4 by using an aqueous organic solvent, wherein the aqueous organic solvent is one of aqueous solutions of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content of the solid mixture is 20 to 80 weight percent;
s6, desorbing the chromatographic column, wherein the adopted silica gel column is one of C1, C4, C8 and C18 reverse phase silica gel, the desorbent is one of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran aqueous organic solvent, and the water content is 30 to 70 weight percent;
s7, collecting a desorbent containing a target product;
and S8, concentrating the desorbent containing the target product to obtain the reference marker for detecting the everolimus impurities.
The reference marker for detecting the everolimus impurities and the preparation method thereof provide the reference marker with the structure the same as or similar to that of chemical derivatives, synthesis byproducts and degradation products in the everolimus impurities and the preparation method thereof, and effectively improve the scientificity and accuracy of the everolimus impurity detection.
Drawings
FIG. 1 is a schematic flow chart of a preparation method of a reference marker for everolimus impurity detection in the present invention.
The reference marker for detecting everolimus impurities and the preparation method thereof according to the present invention will be further described with reference to the accompanying drawings and the detailed description.
Detailed Description
Fig. 1 is a schematic flow chart of a preparation method of a reference marker for everolimus impurity detection of the present invention, and it can be seen from the figure that the reference marker for everolimus impurity detection of the present invention is a degradation product of everolimus, and its structure is:
according to the preparation method of the reference marker for detecting the everolimus impurities, provided by the invention, the solid everolimus is dissolved by using an alkali solution, excessive alkali is neutralized by using an organic acid after heating reaction, and a neutralized mixture is concentrated into a mixture solid; dissolving the mixture solid by using an aqueous organic solvent, desorbing the chromatographic column by using the aqueous organic solvent as a desorbent, collecting the desorbent containing the target product in sections, and concentrating to obtain a reference marker for detecting the everolimus impurities; wherein,
the alkali solution is one of sodium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium hydroxide, dipotassium hydrogen phosphate and potassium dihydrogen phosphate, and the concentration of the solution is 0.2 to 0.7 mol/L;
the heating reaction temperature is 20 to 90 ℃;
the organic acid is one of formic acid, acetic acid, oxalic acid, benzoic acid and succinic acid;
the concentration temperature is 30-60 ℃, and a rotary evaporator is adopted for concentration;
the water-containing organic solvent is one of water solutions of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content of the water-containing organic solvent is 20 to 80 weight percent;
the silica gel column is one of C1, C4, C8 and C18 reverse phase silica gel;
the desorbent is one of water-containing organic solvents of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content is 30-70 wt%.
The preparation method of the reference marker for detecting the everolimus impurities comprises the following steps:
s1, dissolving everolimus solid by adopting an alkali solution, wherein the alkali solution is one of sodium hydroxide, sodium dihydrogen phosphate, disodium hydrogen phosphate, potassium hydroxide, dipotassium hydrogen phosphate and potassium dihydrogen phosphate, and the concentration of the solution is 0.2-0.7 mol/L;
s2, heating for reaction, wherein the heating reaction temperature is 20-90 ℃;
s3, neutralizing the everolimus solution by using organic acid, wherein the organic acid is one of formic acid, acetic acid, oxalic acid, benzoic acid and succinic acid;
s4, concentrating the mixture, and concentrating the mixture at 30-60 ℃ by adopting a rotary evaporator to prepare a mixture solid;
s5, dissolving the solid mixture prepared in the step S4 by using an aqueous organic solvent, wherein the aqueous organic solvent is one of aqueous solutions of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran, and the water content of the solid mixture is 20 to 80 weight percent;
s6, desorbing the chromatographic column, wherein the adopted silica gel column is one of C1, C4, C8 and C18 reverse phase silica gel, the desorbent is one of methanol, ethanol, isopropanol, acetone, acetonitrile and tetrahydrofuran aqueous organic solvent, and the water content is 30 to 70 weight percent;
s7, collecting a desorbent containing a target product;
and S8, concentrating the desorbent containing the target product to obtain the reference marker for detecting the everolimus impurities.
Example 1
10.00g of everolimus was dissolved in 50ml of 0.5mol/L sodium dihydrogen phosphate solution, heated to 35 ℃ for 30min, then adjusted to neutral with acetic acid, and concentrated at 40 ℃ by a rotary evaporator to obtain 10.23g of a mixture solid.
Example 2
Dissolving 12.00g everolimus in 60ml 0.6mol/L disodium hydrogen phosphate solution, heating to 40 deg.C, heating for 45min, adjusting pH to neutral with acetic acid, and concentrating at 45 deg.C with rotary evaporator to obtain 12.13g mixture solid.
Example 3
10.00g of everolimus was dissolved in 50ml of 0.5mol/L disodium hydrogenphosphate solution, heated to 40 ℃ for 40min, adjusted to neutral with formic acid, and concentrated at 45 ℃ using a rotary evaporator to obtain 10.17g of a mixture solid.
Example 4
Dissolving 5g of the concentrated mixture solid (the content of the reference marker for detecting the everolimus impurities is 35.77 percent, and the detection is carried out by adopting a high performance liquid chromatography area normalization method), using 100ml of acetone with the concentration of 60 percent by weight to dissolve the mixture solid, feeding the mixture solid into a 1000ml of reverse phase C4 silica gel chromatographic column, using acetone with the concentration of 73 percent by weight as a desorbent, desorbing the chromatographic column, collecting the mixture in sections, monitoring the liquid phase, combining and concentrating the mixture solid to obtain 1.6g of the reference marker for detecting the everolimus impurities, wherein the content of the reference marker for detecting the everolimus impurities is 95.33 percent, the content of the everolimus is 2.31 percent, and the content of other impurities is 2.36 percent.
Example 5
Dissolving 3g of the concentrated mixture solid (the content of the reference marker for detecting everolimus impurities is 44.28 percent and detecting the everolimus impurities by adopting a high performance liquid chromatography area normalization method) by using 100ml of 65 weight percent isopropanol, feeding the solution into a 1000ml of reverse phase C8 silica gel chromatographic column, using 76 weight percent isopropanol as a desorbent, desorbing the chromatographic column, collecting the solution in sections, monitoring the liquid phase, merging and concentrating the solution to obtain 0.83g of the reference marker for detecting everolimus impurities, wherein the content of the reference marker for detecting everolimus impurities is 96.18 percent, the content of everolimus is 2.17 percent and the content of other impurities is 1.65 percent.
Example 6
Dissolving 5g of the concentrated mixture solid (the content of the reference marker for detecting the everolimus impurities is 48.97 percent and the detection is carried out by adopting a high performance liquid chromatography area normalization method) by using 100ml of acetonitrile with the concentration of 45 percent by weight, feeding the mixture solid into a 1000ml of reverse phase C8 silica gel chromatographic column, using acetonitrile with the concentration of 58 percent by weight as a desorbent, desorbing the chromatographic column, collecting the mixture in sections, monitoring the liquid phase, combining and concentrating the mixture to obtain 1.34g of the reference marker for detecting the everolimus impurities, wherein the content of the reference marker for detecting the everolimus impurities is 97.02 percent, the content of the everolimus is 1.31 percent and the content of other impurities is 1.67 percent.
From the above examples, it can be seen that the reference marker for everolimus impurity detection of the present invention is a degradation product of everolimus, and the structure of the reference marker is the same as or similar to that of a chemical derivative, a synthesis byproduct and a degradation product in everolimus impurities, so that the scientificity and accuracy of everolimus impurity detection can be effectively improved.
Obviously, the reference marker for detecting the everolimus impurities and the preparation method thereof provide the reference marker with the structure the same as or similar to that of chemical derivatives, synthesis byproducts and degradation products in the everolimus impurities and the preparation method thereof, and effectively improve the scientificity and accuracy of the everolimus impurity detection.

Claims (2)

CN201310300574.6A2013-07-172013-07-17Everolimus defects inspecting reference marker and preparation method thereofActiveCN103387572B (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN201310300574.6ACN103387572B (en)2013-07-172013-07-17Everolimus defects inspecting reference marker and preparation method thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN201310300574.6ACN103387572B (en)2013-07-172013-07-17Everolimus defects inspecting reference marker and preparation method thereof

Publications (2)

Publication NumberPublication Date
CN103387572A CN103387572A (en)2013-11-13
CN103387572Btrue CN103387572B (en)2015-09-30

Family

ID=49532004

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN201310300574.6AActiveCN103387572B (en)2013-07-172013-07-17Everolimus defects inspecting reference marker and preparation method thereof

Country Status (1)

CountryLink
CN (1)CN103387572B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP4519689A1 (en)*2022-05-022025-03-12Roche Diagnostics GmbHHemolysis and derivatization reagents and methods for determining lactone analytes
CN115716839A (en)*2022-11-152023-02-28无锡福祈制药有限公司 A kind of synthetic method of everolimus impurity

Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1694736A (en)*2002-09-062005-11-09艾博特公司Medical devices containing hydration inhibitors
CN102215682A (en)*2008-03-112011-10-12万能医药公司 Macrolide compounds and methods of their use
CN102268015A (en)*2011-08-302011-12-07成都摩尔生物医药有限公司Synthesis method of everolimus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2008082982A1 (en)*2006-12-292008-07-10Abbott LaboratoriesImproved assay for immunosuppressant drugs
EP2118654B1 (en)*2006-12-292013-03-27Abbott LaboratoriesDiagnostic test for the detection of a molecule or drug in whole blood

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CN1694736A (en)*2002-09-062005-11-09艾博特公司Medical devices containing hydration inhibitors
CN102215682A (en)*2008-03-112011-10-12万能医药公司 Macrolide compounds and methods of their use
CN102268015A (en)*2011-08-302011-12-07成都摩尔生物医药有限公司Synthesis method of everolimus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Juan I. Luengo 等.Studies on the Chemistry of Rapamycin:Novel Transformations under Lewis-Acid Catalysis.《Tetrahedron Letters》.1993,第34卷(第6期),第991-994页.*
Vidal, Christian;Kirchner, Gabriele I.;Sewing, Karl-Friedrich.Structural Elucidation by Electrospray Mass Spectrometry: An Approach to the In Vitro Metabolism of the Macrolide Immunosuppressant SDZ RAD.《Journal of the American Society for Mass Spectrometry》.1998,第9卷(第12期),第1267-1274页.*

Also Published As

Publication numberPublication date
CN103387572A (en)2013-11-13

Similar Documents

PublicationPublication DateTitle
CN108689905B (en)Vildagliptin impurity compound, and preparation method, detection method and application thereof
EP3822259B1 (en)Method for synthesizing valsartan
CN103387572B (en)Everolimus defects inspecting reference marker and preparation method thereof
AU2021357815A1 (en)Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
CN105524127A (en)Gastrodin compound and preparation thereof
Silvio et al.Forced degradation study of thiocolchicoside: characterization of its degradation products
CN106749258B (en)Method for purifying ertapenem sodium
Sonune et al.Isolation, characterization of degradation products of sitagliptin and development of validated stability-indicating HPLC assay method for sitagliptin API and tablets
CN110143957B (en)Preparation method of cefditoren pivoxil ring-opening product
CN104163769B (en)A kind of preparation method of chlorination propionyl-L-carnitine
CN108424418A (en)A kind of Flomoxef sodium impurity
CN104844604B (en)A kind of preparation method of allopurinol sodium
CN104650140A (en)Preparation method of high purity fosfluconazole
JP6618605B2 (en) A composition containing 3-hydroxy-3-methylbutanoic acid or a salt thereof
CN115785095B (en)Preparation and purification method of moxifloxacin impurity RC-4
CN106117244A (en)The process for purification of Cefditoren pivoxil Cephalosporins
CN114349698B (en)Preparation and purification method of liensinine perchlorate
FI57589C (en) REFERENCE TO A FRAME TRACTOR 6-SUBSTITUTE 3-CARBETOXYHYDRAZINOPYRIDAZINER
CN106083689A (en)A kind of new preparation process of Silodosin compound
CN114276293B (en) A kind of preparation and purification method of methylnexinine perchlorate
CN114349697B (en)Preparation and purification method of isoliensinine perchlorate
CN113549054A (en)Vonoprazan fumarate intermediate and preparation method thereof
CN112028947B (en)Synthetic method of tribenoside
CN103073478B (en)Chemical synthetic method for pyrrole derivatives
US10695450B2 (en)Synthesis of a radioactive agent composition

Legal Events

DateCodeTitleDescription
C06Publication
PB01Publication
C10Entry into substantive examination
SE01Entry into force of request for substantive examination
C14Grant of patent or utility model
GR01Patent grant
PE01Entry into force of the registration of the contract for pledge of patent right
PE01Entry into force of the registration of the contract for pledge of patent right

Denomination of invention:Reference marker for everolimus impurity detection and preparation method thereof

Effective date of registration:20190425

Granted publication date:20150930

Pledgee:Chengdu technical transformation incubator management Co., Ltd.

Pledgor:Chengdu Yatu Biotechnology Co., Ltd.

Registration number:2019510000049

PC01Cancellation of the registration of the contract for pledge of patent right
PC01Cancellation of the registration of the contract for pledge of patent right

Date of cancellation:20200708

Granted publication date:20150930

Pledgee:Chengdu technical transformation incubator management Co.,Ltd.

Pledgor:YACHT BIOTECHNOLOGY Co.

Registration number:2019510000049


[8]ページ先頭

©2009-2025 Movatter.jp